Latest & greatest articles for hiv

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on hiv or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on hiv and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for hiv

161. Invisible work: Child work in households with a person living with HIV/AIDS in Central Uganda

Invisible work: Child work in households with a person living with HIV/AIDS in Central Uganda 28969498 2018 07 02 2018 11 13 1813-4424 14 1 2017 12 SAHARA J : journal of Social Aspects of HIV/AIDS Research Alliance SAHARA J Invisible work: Child work in households with a person living with HIV/AIDS in Central Uganda. 93-109 10.1080/17290376.2017.1379429 HIV/AIDS has led to increased mortality and morbidity, negatively impacting adult labour especially in HIV/AIDS burdened Sub-Saharan Africa (...) . There has been some exploration of the effects of HIV/AIDS on paid child labour, but little empirical work on children's non-paid child work. This paper provides quantitative evidence of how child and household-level factors affect children's involvement in both domestic and family farm work for households with a person living with HIV/AIDS (PLWHA) compared to non-PLWHA households using the 2010/2011 Centre for Health Economics Uganda HIV questionnaire Survey. Descriptive analysis and multivariate

SAHARA J : journal of Social Aspects of HIV/AIDS Research Alliance2017 Full Text: Link to full Text with Trip Pro

162. Biobehavioural survey guidelines for populations at risk for HIV

Biobehavioural survey guidelines for populations at risk for HIV Global HIV Strategic Information Working Group Biobehavioural Survey Guidelines For Populations At Risk For HIVAuthorship and acknowledgements Authors Abu Abdul-Quader, Mark Berry, Trista Bingham, Janet Burnett, Maxia Dong, Amy Drake, Avi Hakim, Wolfgang Hladik, Angele Marandet, Anne McIntyre, Chris Murrill, Joyce Neal and Nita Patel of the US Centers for Disease Control and Prevention (CDC); Rajatashuvra Adhikary (formerly of FHI (...) Mills of FHI 360; staff of the Joint United Nations Programme on HIV/AIDS (UNAIDS); Jesus Garcia Calleja of WHO; Thomas Rehle of the Human Sciences Research Council (HSRC); Tobi Saidel of PEMA Partners; and Ted Alcorn of the Bill & Melinda Gates Foundation. Reviewers Maxia Dong, Shahul Ebrahim, Avi Hakim, Wolfgang Hladik, Amy Herman-Roloff, Andrea Kim, Rachel Kwezi, Sheryl Lyss, John Macom, Chris Murrill, Patrick Nadol, Sanny Chen Northbrook, Bharat Parekh, Nita Patel, Dimitri Prybylski, Ray

World Health Organisation HIV Guidelines2017

163. Maraviroc (Celsentri) - for treatment-experienced adolescents and children of 2 years and older and weighing at least 10kg infected with only CCR5-tropic HIV-1 detectable

Maraviroc (Celsentri) - for treatment-experienced adolescents and children of 2 years and older and weighing at least 10kg infected with only CCR5-tropic HIV-1 detectable Published 09 October 2017 Statement of Advice: maraviroc 20mg/mL oral solution, 25mg, 75mg, 150mg and 300mg film-coated tablets (Celsentri ® ) SMC No 1282/17 ViiV Healthcare UK Ltd 8 September 2017 ADVICE: in the absence of a submission from the holder of the marketing authorisation maraviroc (Celsentri ® ) is not recommended (...) for use within NHS Scotland. Indication under review: In combination with other antiretroviral medicinal products for treatment-experienced adolescents and children of 2 years and older and weighing at least 10kg infected with only CCR5-tropic HIV-1 detectable. The holder of the marketing authorisation has not made a submission to SMC regarding this product in this indication. As a result we cannot recommend its use within NHSScotland. Advice context: No part of this advice may be used without

Scottish Medicines Consortium2017

164. Darunavir / cobicistat / emtricitabine / tenofovir alafenamide (Symtuza) - HIV Infections

Darunavir / cobicistat / emtricitabine / tenofovir alafenamide (Symtuza) - HIV Infections 30 Churchill Place ? Canary Wharf ? London E14 5EU ? United Kingdom An agency of the European Union Telephone +44 (0)20 3660 6000 Facsimile +44 (0)20 3660 5520 Send a question via our website www.ema.europa.eu/contact © European Medicines Agency, 2017. Reproduction is authorised provided the source is acknowledged. 20 July 2017 EMA/496527/2017 Committee for Medicinal Products for Human Use (CHMP (...) disoproxil fumarate GC Gas Chromatography HDL high density lipoprotein HDPE High Density Polyethylene HIV-1/2 human immunodeficiency virus type 1 or type 2 Assessment report EMA/496527/2017 Page 6/106 HPLC High performance liquid chromatography ICH International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use ICP-MS Inductively coupled plasma mass spectrometry IDV indinavir INSTI integrase strand-transfer inhibitor IPC In-process control IR Infrared

European Medicines Agency - EPARs2017

165. HIV and Chronic Pain, Part 2: Addressing the Opioid Public Health Crisis

HIV and Chronic Pain, Part 2: Addressing the Opioid Public Health Crisis 29662723 2018 11 14 2168-3808 35 4 2017 Oct Rehabilitation oncology (American Physical Therapy Association. Oncology Section) Rehabil Oncol HIV and Chronic Pain, Part 2: Addressing the Opioid Public Health Crisis. 197-198 Pullen Sara D SD Emory University School of Medicine, Department of Rehabilitation Medicine, Atlanta, GA 30322. eng P30 AI050409 AI NIAID NIH HHS United States Journal Article United States Rehabil Oncol

Rehabilitation oncology (American Physical Therapy Association. Oncology Section)2017 Full Text: Link to full Text with Trip Pro

166. HIV Testing in Urban Transgender Individuals: A Descriptive Study

HIV Testing in Urban Transgender Individuals: A Descriptive Study 29159309 2018 11 13 2380-193X 2 1 2017 Transgender health Transgend Health HIV Testing in Urban Transgender Individuals: A Descriptive Study. 151-155 10.1089/trgh.2016.0047 HIV testing is considered the initial component of HIV eradication strategies. This study aimed to describe HIV testing in urban, transgender individuals in western New York. The study uses HIV testing intake data from a sample of self-identified transgender (...) males and females volunteering for an HIV test at a community-based healthcare organization. Transgender individuals with some characteristics were found to have more HIV tests including female gender, black, HIV status (positive), a history of incarceration, sex worker, housing situation, and self-referral. The findings can be used to tailor future interventions to encourage HIV testing in transgender populations. Juarez-Cuellar Adrian A School of Nursing, The State University of New York

Transgender health2017 Full Text: Link to full Text with Trip Pro

167. Introducing visual participatory methods to develop local knowledge on HIV in rural South Africa

Introducing visual participatory methods to develop local knowledge on HIV in rural South Africa 29071128 2018 11 13 2059-7908 2 3 2017 BMJ global health BMJ Glob Health Introducing visual participatory methods to develop local knowledge on HIV in rural South Africa. e000231 10.1136/bmjgh-2016-000231 South Africa is a country faced with complex health and social inequalities, in which HIV/AIDS has had devastating impacts. The study aimed to gain insights into the perspectives of rural (...) communities on HIV-related mortality. A participatory action research (PAR) process, inclusive of a visual participatory method (Photovoice), was initiated to elicit and organise local knowledge and to identify priorities for action in a rural subdistrict underpinned by the Agincourt Health and Socio-Demographic Surveillance System (HDSS). We convened three village-based discussion groups, presented HDSS data on HIV-related mortality, elicited subjective perspectives on HIV/AIDS, systematised these into

BMJ global health2017 Full Text: Link to full Text with Trip Pro

168. Exploration of reproductive healthcare needs among adult men regarding sexual transmitted diseases and HIV/AIDS

Exploration of reproductive healthcare needs among adult men regarding sexual transmitted diseases and HIV/AIDS 29038705 2018 11 13 2008-5842 9 9 2017 Sep Electronic physician Electron Physician Exploration of reproductive healthcare needs among adult men regarding sexual transmitted diseases and HIV/AIDS. 5250-5256 10.19082/5250 One of the most important public health issues is men's sexual and reproductive health. Men are the most important counterparts in the prevention of sexual transmitted (...) diseases and HIV/AIDS. A low level of men's referral to utilize healthcare services and the stigmatization of reporting sexually transmitted diseases in society due to cultural issues calls for the designation of strategies for improving the men's healthcare conditions. In addition, it is required to assess men's healthcare needs with consideration of cultural-contextual, social, and economic issues. The aim of this study was to explore the reproductive healthcare needs of men regarding sexual

Electronic physician2017 Full Text: Link to full Text with Trip Pro

169. Rethinking HIV-prevention for school-going young people based on current behaviour patterns

Rethinking HIV-prevention for school-going young people based on current behaviour patterns 28934898 2018 07 02 2018 11 13 1813-4424 14 1 2017 12 SAHARA J : journal of Social Aspects of HIV/AIDS Research Alliance SAHARA J Rethinking HIV-prevention for school-going young people based on current behaviour patterns. 64-76 10.1080/17290376.2017.1376704 The aim of the research was to gain increased knowledge regarding the sexual risk behaviour of school-going young people in South Africa after two (...) decades of HIV-education in schools, to contribute to the development of improved HIV prevention strategies. In collaboration with the Department of Education, a sample of 5305 learners (between 10 and 18 years in Grades 5-12) from high-risk communities were identified. They completed a survey that assessed self-reported sexual risk behaviour and variables that potentially underlie sexual risk, such as attitudes towards preventive behaviour, perceived social norms and self-efficacy (based

SAHARA J : journal of Social Aspects of HIV/AIDS Research Alliance2017 Full Text: Link to full Text with Trip Pro

170. Life skills as a behaviour change strategy in the prevention of HIV and AIDS: Perceptions of students in an open and distance learning institution

Life skills as a behaviour change strategy in the prevention of HIV and AIDS: Perceptions of students in an open and distance learning institution 28934916 2018 07 02 2018 11 13 1813-4424 14 1 2017 12 SAHARA J : journal of Social Aspects of HIV/AIDS Research Alliance SAHARA J Life skills as a behaviour change strategy in the prevention of HIV and AIDS: Perceptions of students in an open and distance learning institution. 77-84 10.1080/17290376.2017.1374878 The prevention of HIV and AIDS (...) , especially amongst young people, is very important, as they are the future leaders. South Africa carries a high burden of the HIV and AIDS disease, and efforts at the prevention of the disease need to be intensified. University students are also at risk, and prevention efforts need to be intensified to ensure that students graduate and enter the world of work to become productive citizens. Failure to pay attention to preventative behaviour amongst university students may have negative socio-economic

SAHARA J : journal of Social Aspects of HIV/AIDS Research Alliance2017 Full Text: Link to full Text with Trip Pro

171. The Achilles’ heel of prevention to mother-to-child transmission of HIV: Protocol implementation, uptake, and sustainability

The Achilles’ heel of prevention to mother-to-child transmission of HIV: Protocol implementation, uptake, and sustainability 28922974 2018 07 02 2018 11 13 1813-4424 14 1 2017 12 SAHARA J : journal of Social Aspects of HIV/AIDS Research Alliance SAHARA J The Achilles' heel of prevention to mother-to-child transmission of HIV: Protocol implementation, uptake, and sustainability. 38-52 10.1080/17290376.2017.1375425 The Joint United Nations Programme on HIV and AIDS proposed to reduce (...) the vertical transmission of HIV from ∼72,200 to ∼8300 newly infected children by 2015 in South Africa (SA). However, cultural, infrastructural, and socio-economic barriers hinder the implementation of the prevention of mother-to-child transmission (PMTCT) protocol, and research on potential solutions to address these barriers in rural areas is particularly limited. This study sought to identify challenges and solutions to the implementation, uptake, and sustainability of the PMTCT protocol in rural SA

SAHARA J : journal of Social Aspects of HIV/AIDS Research Alliance2017 Full Text: Link to full Text with Trip Pro

172. Contemporary HIV/AIDS research: Insights from knowledge management theory

Contemporary HIV/AIDS research: Insights from knowledge management theory 28922967 2018 07 02 2018 11 13 1813-4424 14 1 2017 12 SAHARA J : journal of Social Aspects of HIV/AIDS Research Alliance SAHARA J Contemporary HIV/AIDS research: Insights from knowledge management theory. 53-63 10.1080/17290376.2017.1375426 Knowledge management as a field is concerned with the management of knowledge, including the management of knowledge in research processes. Knowledge management theory has (...) the potential to support research into problems such as HIV, antibiotic resistance and others, particularly in terms of aspects of scientific research related to the contribution of social science. To date, however, these challenges remain with us, and theoretical contributions that can complement natural science efforts to eradicate these problems are needed. This paper seeks to offer a theoretical contribution grounded in Kuhn's paradigm theory of innovation, and in the argument by Lakatos that scientific

SAHARA J : journal of Social Aspects of HIV/AIDS Research Alliance2017 Full Text: Link to full Text with Trip Pro

173. Anal sexual experience and HIV risk awareness among female sex workers in Dire Dawa, eastern Ethiopia

Anal sexual experience and HIV risk awareness among female sex workers in Dire Dawa, eastern Ethiopia 29202095 2018 11 13 2397-0642 2 2017 Global health research and policy Glob Health Res Policy Anal sexual experience and HIV risk awareness among female sex workers in Dire Dawa, eastern Ethiopia. 27 10.1186/s41256-017-0047-6 Female sex workers have been disproportionately affected with HIV and anal sexual experience elevate their vulnerability. Anal intercourse has more risk of HIV (...) transmission than vaginal intercourse for receptors that coupled with low condom and proper lubricant use behavior during anal sex. Besides majority of them did not understand HIV transmission risk of anal intercourse. In Ethiopia, studies on anal sexual experience is almost none existent, so the purpose of this study is to explored anal sexual experience and HIV transmission risk awareness among female sex worker in Dire Dawa, Eastern Ethiopia. Qualitative study with thematic analysis approach

Global health research and policy2017 Full Text: Link to full Text with Trip Pro

174. [Dolutegravir (HIV infection) - benefit assessment according to õ35a Social Code Book V]

[Dolutegravir (HIV infection) - benefit assessment according to õ35a Social Code Book V] Dolutegravir (HIV-Infektion): nutzenbewertung gemäß § 35a SGB V; dossierbewertung; auftrag A17-11 [Dolutegravir (HIV infection) - benefit assessment according to §35a Social Code Book V] Dolutegravir (HIV-Infektion): nutzenbewertung gemäß § 35a SGB V; dossierbewertung; auftrag A17-11 [Dolutegravir (HIV infection) - benefit assessment according to §35a Social Code Book V] Institut für Qualität und (...) Wirtschaftlichkeit im Gesundheitswesen Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen. Dolutegravir (HIV-Infektion): nutzenbewertung gemäß § 35a SGB V; dossierbewertung; auftrag A17-11. [Dolutegravir (HIV infection) - benefit assessment according to §35a Social Code Book V] Cologne: Institut

Health Technology Assessment (HTA) Database.2017

175. Bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection (GS-US-380-1489): a double-blind, multicentre, phase 3, randomised controlled non-inferiority trial.

Bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection (GS-US-380-1489): a double-blind, multicentre, phase 3, randomised controlled non-inferiority trial. BACKGROUND: Integrase strand transfer inhibitors (INSTIs) are recommended components of initial antiretroviral therapy with two nucleoside reverse transcriptase inhibitors. Bictegravir is a novel, potent INSTI with a high in-vitro barrier to resistance (...) enrolled HIV-1 infected adults (aged ≥18 years) who were previously untreated (HIV-1 RNA ≥500 copies per mL); HLA-B*5701-negative; had no hepatitis B virus infection; screening genotypes showing sensitivity to emtricitabine, tenofovir, lamivudine, and abacavir; and an estimated glomerular filtration rate of 50 mL/min or more. Participants were randomly assigned (1:1), via a computer-generated allocation sequence (block size of four), to receive coformulated bictegravir 50 mg, emtricitabine 200 mg

Lancet2017

176. Coformulated bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir with emtricitabine and tenofovir alafenamide, for initial treatment of HIV-1 infection (GS-US-380-1490): a randomised, double-blind, multicentre, phase 3, non-inferiori

Coformulated bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir with emtricitabine and tenofovir alafenamide, for initial treatment of HIV-1 infection (GS-US-380-1490): a randomised, double-blind, multicentre, phase 3, non-inferiori BACKGROUND: Integrase strand transfer inhibitors (INSTIs) coadministered with two nucleoside or nucleotide reverse transcriptase inhibitors (NRTIs) are recommended as first-line treatment for HIV, and coformulated fixed-dose combinations (...) are preferred to facilitate adherence. We report 48-week results from a study comparing initial HIV-1 treatment with bictegravir-a novel INSTI with a high in-vitro barrier to resistance and low potential as a perpetrator or victim of clinically relevant drug interactions-coformulated with the NRTI combination emtricitabine and tenofovir alafenamide as a fixed-dose combination to dolutegravir administered with coformulated emtricitabine and tenofovir alafenamide. METHODS: In this randomised, double-blind

Lancet2017

177. HIV Pre-Exposure Prophylaxis with Emtricitabine/Tenofovir Disoproxil Fumarate — Regulatory and Reimbursement Policies

HIV Pre-Exposure Prophylaxis with Emtricitabine/Tenofovir Disoproxil Fumarate — Regulatory and Reimbursement Policies HIV Pre-Exposure Prophylaxis with Emtricitabine/Tenofovir Disoproxil Fumarate — Regulatory and Reimbursement Policies | CADTH.ca CADTH Document Viewer HIV Pre-Exposure Prophylaxis with Emtricitabine/Tenofovir Disoproxil Fumarate — Regulatory and Reimbursement Policies Table of Contents Search this document HIV Pre-Exposure Prophylaxis with Emtricitabine/Tenofovir Disoproxil (...) Fumarate — Regulatory and Reimbursement Policies August 2017 Context Infection with the HIV continues to be a public health concern in Canada. Despite the wide availability and effectiveness of condoms in reducing sexual transmission, new HIV infections occur annually. The Public Health Agency of Canada estimated that 2,570 new infections (range: 1,940 to 3,200) occurred in Canada in 2014; 1 of these, 54.3% were in sexually active men who have sex with other men (MSMs). 2 HIV infection can

Canadian Agency for Drugs and Technologies in Health - Environmental Scanning2017

178. HIV Pre-Exposure Prophylaxis with Emtricitabine/Tenofovir Disoproxil Fumarate — Regulatory and Reimbursement Policies

HIV Pre-Exposure Prophylaxis with Emtricitabine/Tenofovir Disoproxil Fumarate — Regulatory and Reimbursement Policies HIV Pre-Exposure Prophylaxis with Emtricitabine/Tenofovir Disoproxil Fumarate — Regulatory and Reimbursement Policies | CADTH.ca CADTH Document Viewer HIV Pre-Exposure Prophylaxis with Emtricitabine/Tenofovir Disoproxil Fumarate — Regulatory and Reimbursement Policies Table of Contents Search this document HIV Pre-Exposure Prophylaxis with Emtricitabine/Tenofovir Disoproxil (...) Fumarate — Regulatory and Reimbursement Policies August 2017 Context Infection with the HIV continues to be a public health concern in Canada. Despite the wide availability and effectiveness of condoms in reducing sexual transmission, new HIV infections occur annually. The Public Health Agency of Canada estimated that 2,570 new infections (range: 1,940 to 3,200) occurred in Canada in 2014; 1 of these, 54.3% were in sexually active men who have sex with other men (MSMs). 2 HIV infection can

Canadian Agency for Drugs and Technologies in Health - Environmental Scanning2017

179. Isoniazid for preventing tuberculosis in HIV-infected children.

Isoniazid for preventing tuberculosis in HIV-infected children. BACKGROUND: Tuberculosis (TB) is an important cause of illness and death in HIV-positive children living in areas of high TB prevalence. We know that isoniazid prophylaxis prevents TB in HIV-negative children following TB exposure, but there is uncertainty related to its role in TB preventive treatment in HIV-positive children. OBJECTIVES: To summarise the effects of TB preventive treatment versus placebo in HIV-positive children (...) with no known TB contact on active TB, death, and reported adverse events. SEARCH METHODS: We searched the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE/PubMed, Embase and two trial registers up to February 2017. SELECTION CRITERIA: We included trials of HIV-positive children with and without known TB exposure, randomized to receive TB preventive treatment or placebo. DATA COLLECTION AND ANALYSIS: Two review authors independently used the study selection criteria, assessed risk of bias

Cochrane2017 Full Text: Link to full Text with Trip Pro

180. Do Less Harm: Evaluating HIV Programmatic Alternatives in Response to Cutbacks in Foreign Aid.

Do Less Harm: Evaluating HIV Programmatic Alternatives in Response to Cutbacks in Foreign Aid. Background: Resource-limited nations must consider their response to potential contractions in international support for HIV programs. Objective: To evaluate the clinical, epidemiologic, and budgetary consequences of alternative HIV program scale-back strategies in 2 recipient nations, the Republic of South Africa (RSA) and Côte d'Ivoire (CI). Design: Model-based comparison between current standard (...) (CD4 count at presentation of 0.260 × 109 cells/L, universal antiretroviral therapy [ART] eligibility, and 5-year retention rate of 84%) and scale-back alternatives, including reduced HIV detection, no ART or delayed initiation (when CD4 count is <0.350 × 109 cells/L), reduced investment in retention, and no viral load monitoring or second-line ART. Data Sources: Published RSA- and CI-specific estimates of the HIV care continuum, ART efficacy, and HIV-related costs. Target Population: HIV

Annals of Internal Medicine2017 Full Text: Link to full Text with Trip Pro